The diagnosis and management of colorectal cancer (CRC) has been impacted by the
discovery and validation of a wide variety of biomarkers designed to facilitate a personalized …

Background The FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) regimen has
been shown to be better than FOLFIRI (fluorouracil, folinate, and irinotecan) in a phase 3 …

As proteomics technologies develop, increasing number of membrane-associated proteins
specific for cancer cells are being discovered. These proteins are of great interest …

Background: The identification of molecular and genetic markers to predict or monitor the
efficacy of bevacizumab (BV) represents a key issue in the treatment of metastatic colorectal …

Significant progression has been achieved in the treatment of metastatic colorectal cancer
(mCRC) in recent years. This has been partly attributed to successfully incorporating new …

Angiogenesis is a key factor in the carcinogenesis process. In oncological practice,
angiogenesis inhibition, mainly through the blockade of the VEGF family and its receptors …

Introduction: Receptor tyrosine kinases (RTKs) are validated targets for oncology drug
discovery and RTK antagonists are available to treat human malignancies. Nonetheless, the …

Over the past three decades, numerous reports have addressed several aspects of drug
resistance phenomena. However, little is known regarding the impact that dietary …

Colorectal cancer (CRC) has been re-classified based on molecular analyses of various
genes and proteins capable of separating morphologic types of tumors into molecular …

Bevacizumab is the first molecular-targeted antiangiogenic therapy to be approved by the
US FDA and EMEA and, despite the numerous clinical successes, many challenges remain …